Genmab — Maj 2015
-
Phase 2 study of daratumumab (DARA) monotherapy in patients with ≥3 lines of prior therapy or double refractory multiple myeloma (MM): 54767414MMY2002 (Sirius) — Late breaking abstract #LBA8512, Oral Presentation, Tuesday, June 2, 11:21AM to 11:33AM CDT
This abstract has been designated a late breaking abstract and the embargo will be lifted on Saturday May 30 at 6:30AM CDT. The abstract will be included in a press briefing by ASCO on Saturday, May 30 from 8:00AM to 9:00AM CDT. -
Det nærmeste jeg er kommer er punkt 7 på denne liste http://www.asco.org/press-center/annual-meeting-media-resource-center
-
tror ikke vi skal vente os meget af abstractet
-
tror de gemmer alle godterne til på tirsdag i selve præsentationen
-
Hej...så lykkedes det mig at komme ind
-
-
3 sCR , 10 VGPR
-
Time to progression er dog lav med kun 3,7 måneder.
-
Det er dog også virkelig virkelig pretreatet patienter. Prior lines of therapi er over 5 !
-
63% har fået pomalyst og 48% kyprolis inden dara
-
virkelig flot safety profil også
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind